Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCIâs Surveillance, Epidemiology and End... Thank you for visiting nature.com. You…
“We are excited to collaborate with Stanford Medicine and advance the evaluation of STAR-LLD,” said Pedro Lichtinger, Chairman and CEO. “This agreement represents an important step in our strategy, as we believe this combination has the potential to improve CAR-T…
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center. I have had patients who have received this device vs a shot of the…
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with... HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody…
Cleveland Clinic Abu Dhabi has highlighted the importance of a personalised approach to complex plasma cell disorders through the treatment of two patients with... Cleveland Clinic Abu Dhabi treats complex multiple myeloma, rare POEMS cases Cleveland Clinic Abu Dhabi has…
Jessica Silva-Fisher, has received a Research Scholar Grant from the American Cancer Society — one of only 15 investigators nationally to receive the award this grant cycle. She is an assistant professor of medicine at WashU Medicine and a research member at…
AbbVie (NYSE: ABBV) has submitted a Biologics License Application to the FDA for its multiple myeloma candidate etentamig. The filing is backed by a pivotal Phase 3 trial in relapsed or refractory multiple myeloma that met its primary endpoint. Etentamig is…
- Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - About Phase 3 REGAL Trial The Phase 3 REGAL trial (NCT04229979) is a randomized registrational clinical trial evaluating GPS as a…
Anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma that primarily affects T cells. While most cases respond well to conventional chemotherapy, achieving long-term survival rates as high as in 80-90%, a subset of patients require more extensive treatment.
Atrial fibrillation (AF) is a relatively frequent complication after autologous stem cell transplantation in patients with multiple myeloma, one that’s associated with an increased risk of mortality, a retrospective study shows. Factors associated with posttransplant AF in this population include…
Multiple myeloma: new drugs, CAR-T and bispecifics, trial results and living with myeloma.
An article joins this feed when it matches these terms. Each one is also a search of its own.